TY - JOUR
T1 - Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia
AU - Kegyes, David
AU - Jitaru, Ciprian
AU - Ghiaur, Gabriel
AU - Ciurea, Stefan
AU - Hoelzer, Dieter
AU - Tomuleasa, Ciprian
AU - Gale, Robert Peter
N1 - Funding Information:
David Kegyes and Ciprian Jitaru contributed equally to the current manuscript and are both considered first author. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002). CJ is funded by an internal grant of the Iuliu Hatieganu University – School of Doctoral Studies. DK is funded by an internal grant of the Iuliu Hatieganu University – School of Medicine. CT, GG are supported by a grant awarded by the Romanian National Ministry of Research, Innovation and Digitalization: PN-III-P4-ID-PCE-2020-1118 within PNCDI IV, Projects for Exploratory Medicine; Projects for Exploratory Medicine—PCE 225/2021; as well as a national grant awarded to Young Research Teams (PN-III-PI-1.1-TE-2019-0271; as well as by an international collaborative grant of the European Economic Space between Romania and Iceland 2021–2023: “Cooperation strategy for knowledge transfer, internationalization and curricula innovation in the field of research education at the 3rd level of study –AURORA.”. DK and CJ were trained as part of the target group of the AURORA grant (collaborative grant between Romania and European Economical Area) by professor Jon Thor Bergthorsson (University of Iceland, Reykjavik, Iceland), professor Victor Greiff (University of Oslo, Norway) and Dr. Diana Gulei (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania) in modern protocols in molecular biology and translational research; as well as modern protocols in immunotherapy by professor Jo Caers (University of Liege), as a result of a collaborative grant between Romania and Wallonia); both trainings that contributed deeply to understanding of the basic science described in the manuscript. DK, CJ, GG, SC, DH, and CT wrote the manuscript. GG, DH, and SC reviewed and approved the manuscript, as well as provided the funding, as well as the training on DK, CJ and CT. RPG coordinated the manuscript wiring, supervised the work, and reviewed the manuscript.
Funding Information:
David Kegyes and Ciprian Jitaru contributed equally to the current manuscript and are both considered first author. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China ( 84000-51200002 ). CJ is funded by an internal grant of the Iuliu Hatieganu University – School of Doctoral Studies . DK is funded by an internal grant of the Iuliu Hatieganu University – School of Medicine . CT, GG are supported by a grant awarded by the Romanian National Ministry of Research, Innovation and Digitalization : PN-III-P4-ID-PCE-2020-1118 within PNCDI IV, Projects for Exploratory Medicine ; Projects for Exploratory Medicine — PCE 225/2021 ; as well as a national grant awarded to Young Research Teams ( PN-III-PI-1.1-TE-2019-0271 ; as well as by an international collaborative grant of the European Economic Space between Romania and Iceland 2021–2023: “Cooperation strategy for knowledge transfer, internationalization and curricula innovation in the field of research education at the 3rd level of study –AURORA.”. DK and CJ were trained as part of the target group of the AURORA grant (collaborative grant between Romania and European Economical Area ) by professor Jon Thor Bergthorsson ( University of Iceland , Reykjavik, Iceland), professor Victor Greiff ( University of Oslo , Norway) and Dr. Diana Gulei (I uliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca, Romania) in modern protocols in molecular biology and translational research; as well as modern protocols in immunotherapy by professor Jo Caers (University of Liege), as a result of a collaborative grant between Romania and Wallonia); both trainings that contributed deeply to understanding of the basic science described in the manuscript.
Publisher Copyright:
© 2023
PY - 2023/5
Y1 - 2023/5
N2 - About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.
AB - About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.
KW - B-cell acute lymphoblastic leukemia
KW - Blinatumomab
KW - Brexucabtagene autoleucel
KW - Immune therapy
KW - Inotuzumab ozogamicin
KW - Tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85147300060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147300060&partnerID=8YFLogxK
U2 - 10.1016/j.blre.2023.101042
DO - 10.1016/j.blre.2023.101042
M3 - Review article
C2 - 36732205
AN - SCOPUS:85147300060
SN - 0268-960X
VL - 59
JO - Blood Reviews
JF - Blood Reviews
M1 - 101042
ER -